AbbVie Inc (ABBV)vsDefinitive Healthcare Corp (DH)
ABBV
AbbVie Inc
$234.89
+0.06%
HEALTHCARE · Cap: $391.50B
DH
Definitive Healthcare Corp
$0.76
-1.14%
HEALTHCARE · Cap: $85.30M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 26266% more annual revenue ($62.82B vs $238.26M). ABBV leads profitability with a 5.8% profit margin vs -71.5%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
DH
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$234.89
$88.67 premium
Margin of Safety
+78.5%
Fair Value
$7.87
Current Price
$0.76
$7.11 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
ROE of -116.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : DH
The strongest argument for DH centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : DH
The primary concerns for DH are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while DH is a turnaround play — different risk/reward profiles.
DH carries more volatility with a beta of 1.33 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 37/100) and 12.4% revenue growth. DH offers better value entry with a 78.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Definitive Healthcare Corp
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Definitive Healthcare Corp (DH) is a premier provider of comprehensive data and analytics solutions tailored for the healthcare sector, serving a broad spectrum of clients, including pharmaceutical firms, payers, and healthcare providers. The company leverages vast datasets and advanced real-time analytics to drive operational efficiency and provide strategic insights, ultimately enhancing patient outcomes. Positioned at the forefront of a rapidly evolving healthcare landscape, Definitive Healthcare is dedicated to delivering innovative, data-centric solutions that not only optimize operational performance but also confer competitive advantages to its partners. As demand for sophisticated healthcare analytics surges, DH is poised to be an influential player in redefining healthcare delivery.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?